[HLA-B27 polymorphism and spondyloarthropathies]
M J Peixoto1, T Gonzales, H Spinola
1Serviço de Epidemiologia e Biologia Molecular, Hospital de Santo Espírito, Angra do Heroísmo, Açores, Portugal.
Acta Medica Portuguesa
|April 6, 2006
Summary
The human leukocyte antigen B27 (HLA-B27) gene is strongly associated with ankylosing spondylitis (AS). This review covers HLA-B27's structure, variations, and proposed mechanisms linking it to AS pathogenesis.
Area of Science:
- Immunogenetics
- Rheumatology
- Molecular Biology
Context:
- The human leukocyte antigen B27 (HLA-B27) gene is strongly associated with ankylosing spondylitis (AS) and other spondyloarthropathies (SpA).
- This link, discovered in 1973, is one of the most significant HLA-disease associations.
- Understanding the pathogenic mechanism is crucial for developing targeted therapies.
Purpose:
- To review the current knowledge on the structure and polymorphism of the HLA-B27 molecule.
- To describe the main pathogenic hypotheses explaining the association between HLA-B27 and AS.
Summary:
- This review synthesizes current research on HLA-B27, a gene strongly linked to ankylosing spondylitis (AS).
- It details the molecular structure and genetic variations (polymorphism) of HLA-B27.
- The article critically examines leading hypotheses on how HLA-B27 contributes to AS development.
Impact:
- Provides a comprehensive overview of HLA-B27 in relation to AS for researchers and clinicians.
- Highlights key areas for future research into SpA pathogenesis.
- Facilitates a deeper understanding of the molecular basis of autoimmune diseases.
Related Concept Videos
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...